Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by gltainv on Aug 07, 2024 8:26am

Regardless

Whenever the news comes out, it just needs to be something good, either the second tranche or new agreements made, just anything of substance. As much as I think, eventually we'll get there, due to the old quality over quantity argument, it's frustrating that we're kind of in the dark again as we were before that roll of good news. Firm believer, believe we have a great product on our hands, but now getting to market. GL everyone, hope we have reason for cheer!
Comment by Lesalpes29 on Aug 07, 2024 8:52am
And of course something really positive could have an impact on when we will have the next NR. It's not always bad behind the scene! 
Comment by DJDawg on Aug 07, 2024 9:46am
I love the science but this whole email with wording about "early next week" and "can't wait to share" and then nothing so far is eye-rolling classic for TLT management. I love the science but just do a few corporate management things in a way that is not frustrating. Please.
Comment by Gooseybear on Aug 07, 2024 11:51am
Agreed Dawg. These press releases are no better than click bait.
Comment by Mikee3003 on Aug 07, 2024 12:09pm
Just another stellar move by our management team. Enjoy.....  https://youtu.be/XZHXJvVk5Tc?t=33
Comment by Kayz88 on Aug 07, 2024 12:08pm
I took it seriously. Lol. My mistake.
Comment by riverrrow on Aug 07, 2024 9:49am
Are they just waiting for the cheque to clear before they make the big announcement?   I didn't receive "the email" and I'm glad I didn't.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250